Feb 1 | News
Novartis announced today that following a priority review, the FDA has approved an update to the Gleevec (imatinib mesylate) tablets label to recommend 36 months of treatment after surgery for adult patients with KIT (CD117)-positive gastrointestinal stromal tumors (GIST) who met the risk of recurrence inclusion criteria of the pivotal trial.
|
Jan 27 | News
GenVec, Inc., a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines, today announced that it has extended its Research Collaboration and License Agreement with Novartis.
|
Jan 25 | News
Novartis announced Wednesday that net income in the fourth quarter plunged 47 percent to $1.2 billion as the company recorded previously-disclosed charges mainly related to a revision in the sales potential of Rasilez/Tekturna.
|
Jan 18 | News
Novartis said today that it received Chinese regulatory approval for its eye drug Lucentis, and it is launching the diabetes treatment Galvus in China.
|
Jan 16 | Articles
Vaccines continue to be one of the brighter spots for pharmaceutical companies in the current market, and revenues for vaccine products are expected to continue their double-digit growth in the future.
|
Jan 14 | News
Novartis to restructure US business to strengthen competitive position in light of loss of Diovan® patent and announces charge for Rasilez®/Tekturna®
|
Jan 11 | Blogs
It’s only a few weeks in to the New Year and it’s sad to say that 2012 is already shaping up to be as bad as 2011 was in regards to pharmaceutical product recalls.
|
Jan 9 | News
Novartis Consumer Health Inc. voluntarily recalls certain over-the-counter products in the US while Novartis Group strengthens quality standards across all manufacturing sites
|
Dec 23 2011 | News
New Phase III data shows Novartis JAK inhibitor INC424 significantly reduced disease burden in patients with myelofibrosis
|
Dec 23 2011 | News
Novartis pivotal study of Exjade® shows significant reduction of iron overload in patients with non-transfusion-dependent thalassemia
|